TGF-β Receptor

Receptor

Transforming growth factor beta receptors

TGF-β Receptor

TGF-β Receptor Isoform Specific Products:

TGF-β Receptor Related Products (178)
Recombinant Proteins (70)
Antibodies (16)
TGF-β Receptor Isoform Comparison

By Effects:	Controls (5) Inhibitors (134) Ligand (1) Agonists (8) Degraders (2) Antagonists (7) Activators (6) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-10431

SB-431542	Inhibitor	99.85%
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.

HY-13418A

Dorsomorphin	Inhibitor	99.91%
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-10432

A 83-01	Inhibitor	99.41%
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.

HY-13418

Dorsomorphin dihydrochloride	Inhibitor	99.91%
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-12071

LDN193189	Inhibitor	99.48%
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.

HY-P3970D

KQFK TFA	Control	99.12%
KQFK TFA is the TFA salt form of KQFK (HY-P3970C). KQFK TFA is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β.

HY-W028145

TGF-βRI inhibitor 2	Inhibitor	98.32%
TGF-βRI inhibitor 2 (compound 13) is a TGF-βRI inhibitor. TGF-βRI inhibitor 2 can be used in cancer research.

HY-P990974

Bezeotermin alfa
HY-P990974 is an BMP-6-targeting Fusion Protein.

HY-13226

Galunisertib	Inhibitor	99.95%
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-13012

RepSox	Inhibitor	99.92%
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.

HY-12273

DMH-1	Inhibitor	99.95%
DMH-1 is a potent and selective BMP inhibitor with IC₅₀s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

HY-P99355

Bimagrumab	Inhibitor	99.31%
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with K_Ds of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.

HY-12075

LY2109761	Inhibitor	99.72%
LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with K_is of 38 nM and 300 nM, respectively.

HY-12043

SB 525334	Inhibitor	99.97%
SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC₅₀ of 14.3 nM.

HY-12071A

LDN193189 Tetrahydrochloride	Inhibitor	99.86%
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM).

HY-124697

BMP signaling agonist sb4	Agonist	99.98%
BMP signaling agonist sb4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC₅₀ value of 74 nM, activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. BMP signaling agonist sb4 activates BMP4 target genes (inhibitors of DNA binding, Id1 and Id3) canonical BMP signaling.

HY-19928

Vactosertib	Inhibitor	99.58%
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect.

HY-10432A

A 83-01 sodium	Inhibitor	98.43%
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1)	Antagonist	99.77%
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier.

HY-12071B

LDN-193189 dihydrochloride	Inhibitor	99.75%
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.

TGF-β Receptor Isoform Comparison

ALK1

ALK2

ALK3

ALK4

ALK5

ALK6

ALK7

TGFβR2

ACVR2A

ACVR2B

TGF-β Receptor Degraders & Inhibitors

Product Name	ALK1	ALK2	ALK3	ALK4	ALK5	ALK6	ALK7	TGFβR2	ACVR2A	ACVR2B	Purity

SB-431542				ALK4, IC₅₀: 1 μM	ALK5, IC₅₀: 0.75 μM		ALK7, IC₅₀: 2 μM				99.85%
Dorsomorphin		ACVR1	BMPR1A			ALK6					99.91%
A 83-01				ALK4, IC₅₀: 45 nM	ALK5, IC₅₀: 12 nM		ALK7, IC₅₀: 7.5 nM				99.41%
Dorsomorphin dihydrochloride		ACVR1	BMPR1A			ALK6					99.91%
LDN193189		ACVR1, IC₅₀: 5 nM	BMPR1A, IC₅₀: 30 nM								99.48%
RepSox					ALK5, IC₅₀: 4 nM						99.92%
Bimagrumab									ACVR2A, Kd: 434 pM	ACVR2B, Kd: 1.7 pM	99.31%
LDN193189 Tetrahydrochloride		ACVR1, IC₅₀: 5 nM	BMPR1A, IC₅₀: 30 nM								99.86%
Vactosertib					ALK5, IC₅₀: 12.9 nM						99.58%
A 83-01 sodium				ALK4, IC₅₀: 45 nM	ALK5, IC₅₀: 12 nM		ALK7, IC₅₀: 7.5 nM				98.43%
LDN-212854	ALK1, IC₅₀: 2.4 nM	ACVR1, IC₅₀: 1.3 nM	BMPR1A, IC₅₀: 85.8 nM	ALK4, IC₅₀: 2133 nM	ALK5, IC₅₀: 9276 nM						99.70%
Sotatercept									ACVR2A		99.61%
ML347	ALK1, IC₅₀: 46 nM	ACVR1, IC₅₀: 32 nM	BMPR1A, IC₅₀: 10800 nM								99.94%
R-268712					TGFBR1, IC₅₀: 2.5 nM						99.88%
SB-431542 (GMP)				ALK4, IC₅₀: 1 μM	ALK5, IC₅₀: 0.75 μM		ALK7, IC₅₀: 2 μM
Vactosertib Hydrochloride					ALK5, IC₅₀: 12.9 nM						99.22%
OD36		ACVR1, Kd: 37 nM ACVR1, IC₅₀: 47 nM ALK2 R206H, IC₅₀: 22 nM									99.33%
IN-1130					ALK5						99.93%
EW-7195					ALK5, IC₅₀: 4.83 nM						99.20%
AZ12799734	ALK1, Kd: 7.1 μM	ACVR1, Kd: 6.2 μM	BMPR1A, Kd: 40 μM	ALK4, Kd: 1 μM	ALK5, Kd: 0.74 μM TGFBR1, IC₅₀: 47 nM	ALK6, Kd: 0.017 μM					98.07%
Itacnosertib		ACVR1			ALK5						99.06%
Zilurgisertib		ALK2									99.77%
AZ12601011				ALK4			ALK7				99.88%
THRX-144644					ALK5, IC₅₀: 0.14 nM						99.90%
ALK2-IN-2		ACVR1, IC₅₀: 9 nM									99.93%
KER047 succinate		ACVR1									98.93%
KER047		ACVR1									99.35%
ALK5-IN-34					ALK5, IC₅₀: <10 nM						98.21%
TGFBR1-IN-1					ALK5, IC₅₀: 10-100 nM
M4K2281		ALK2, IC₅₀: 2 nM			ALK5, IC₅₀: 350 nM
ALK5-IN-33					ALK5, IC₅₀: ≤10 nM
J-1149					ALK5, IC₅₀: 0.017 μM
TGFβRII-IN-2								TGF-βR2, IC₅₀: 2.4 μM
ALK5-IN-25					ALK5, IC₅₀: ≤10 nM
M4K2308		ALK2, IC₅₀: 2 nM			ALK5, IC₅₀: 224 nM
MU1700	ALK1, IC₅₀: 13 nM	ALK2, IC₅₀: 6 nM				ALK6, IC₅₀: 41 nM
TGFβRII-IN-3								TGF-βR2, IC₅₀: 4.1 μM
ALK5-IN-27					ALK5, IC₅₀: ≤10 nM
OD36 hydrochloride		ACVR1, Kd: 37 nM ACVR1, IC₅₀: 47 nM ALK2 R206H, IC₅₀: 22 nM
J-1063					ALK5
ALK5-IN-28					ALK5, IC₅₀: ≤10 nM
M4K2306		ALK2, IC₅₀: 7 nM			ALK5, IC₅₀: 3915 nM
A 83-01 (Standard)				ALK4, IC₅₀: 45 nM	ALK5, IC₅₀: 12 nM		ALK7, IC₅₀: 7.5 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

TGF-β Receptor

TGF-β Receptor

TGF-β Receptor Isoform Specific Products:

TGF-β Receptor Isoform Specific Products:

TGF-β Receptor Related Products (178)

Recombinant Proteins (70)

Antibodies (16)

TGF-β Receptor Isoform Comparison

TGF-β Receptor Related Products (178):